Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
A new approach to HIV prevention currently being studied includes the use of microbicides,
substances that kill microbes. Tenofovir disoproxil fumarate (TDF) is an oral, FDA-approved,
anti-HIV drug, and tenofovir gel is an experimental microbicide. The purpose of this study is
to determine the adherence and acceptability to and blood levels of three daily regimens of
tenofovir in both oral and gel form.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)